The insider sales are small relative to market cap and likely routine portfolio diversification or tax-related selling, especially given the stock's recent strong performance. However, the cluster of C-suite and director sales in a narrow window is a mild cautionary signal. Monitor for any upcoming negative catalysts (e.g., clinical data readouts, regulatory updates) that could explain the timing. The stock's strong historical momentum suggests the market may not react negatively to these sales alone.
Price Chart
Executive Summary
Three insiders at Spyre Therapeutics, including the CEO and CFO, sold shares totaling $920K over a one-week window. Director Albers Jeffrey W. executed the bulk of the sales ($2.4M across multiple transactions on August 7), including derivative exercises followed by open-market sales. While the dollar amount is modest relative to the $9.3B market cap (~0.01%), the cluster of C-suite and director sales warrants attention, though the historical win rate on SYRE insider clusters is high and the stock has been strong.
Key Financial Metrics
Key Facts
- Three insiders sold shares totaling $920K in a 7-day window ending August 7, 2026.
- Director Albers Jeffrey W. sold $2.4M worth of shares on August 7, including derivative exercises and open-market sales.
- CEO Cameron sold 800 shares at $93.97 for $75K; CFO Burrows sold 100 shares at $97.10 for $10K.
- Total insider sales represent ~0.01% of the $9.3B market cap, which is below the 0.1% threshold for materiality.
- The stock has rallied significantly (T+20 avg alpha +11.77% on prior reports), and the cluster follows a period of strong performance.
Financial Impact
Total insider sales of $920K, or approximately 0.01% of market cap, are trivial in absolute and relative terms.
Risk Factors
- Insider sales could signal a lack of confidence in near-term prospects, though the dollar amounts are too small to be definitive.
- The stock's high valuation ($9.3B market cap for a pre-revenue biotech) creates downside risk if pipeline catalysts disappoint.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-SYRE-1786411948947 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | Insider Cluster | $88.98 $90.80 | ▼ −2.05% | ▼ −3.25% | $93.19 (−4.73%) |
Aug 11, 2026 7w ago | Insider Cluster | $102.74 $107.82 | ▼ −4.94% | ▼ −5.35% | $93.19 (+9.30%) |
Aug 6, 2026 8w ago | Insider Cluster | $103.42 $101.85 | ▲ +1.52% | ▲ +2.73% | $93.19 (+9.89%) |
Jul 3, 2026 13w ago | Insider Cluster | $86.63 $98.75 | ▲ +13.99% | ▲ +13.06% | $93.19 (+7.57%) |
Jun 27, 2026 13w ago | Insider Cluster | $90.16 $88.74 | ▲ +1.57% | ▲ +2.96% | $93.19 (−3.36%) |
Jun 26, 2026 14w ago | S-3ASR | $90.16 $88.74 | ▼ −1.57% | ▼ −2.96% | $93.19 (+3.36%) |
Jun 24, 2026 14w ago | Insider Cluster | $86.24 $88.89 | ▼ −3.07% | ▼ −1.37% | $93.19 (−8.06%) |
Jun 15, 2026 15w ago | 8-K | $83.58 $100.32 | ▲ +20.03% | ▲ +21.41% | $93.19 (+11.50%) |
Jun 12, 2026 16w ago | Institutional Cluster | $80.79 $88.34 | ▲ +9.35% | ▲ +8.67% | $93.19 (+15.35%) |
Jun 11, 2026 16w ago | Institutional Cluster | $80.77 $87.49 | ▲ +8.32% | ▲ +7.89% | $93.19 (+15.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access